Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial

Alette M. Wessels, Bruce G. Pollock, Norbert G. Anyama, Lon S. Schneider, Jeffrey A. Lieberman, Stephen R. Marder, Robert Bies

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial that received risperidone were included in this study. Eighteen subjects completed the study without switching medication (completers on risperidone), whereas 47 discontinued the medication. Those who discontinued were divided into 2 groups according to responsiveness to therapy. Using Cox proportional survival regression analysis, we estimated time to discontinuation and factors associated with treatment discontinuation including age, dose, body mass index, neuropsychiatric inventory baseline score, and average exposure (area under the curve [AUC]) to risperidone and 9-hydroxy risperidone. Twenty-four and 17 subjects discontinued therapy because of inadequate therapeutic effect and side effects, respectively (6 subjects were excluded because of missing information about reason for switching or discontinuation). Discontinuation hazards for those with a higher than median AUC of the metabolite were 2.54 (P = 0.029; inadequate and side effect group combined) and 3.48 (P = 0.025; inadequate effect group) times that of those in the lower than median AUC group. None of the other covariates contributed significantly to the switching hazard. Risperidone metabolite, 9-hydroxy risperidone concentrations, correlated with the risk of switching or discontinuing the medication, suggesting that 9-hydroxy risperidone contributes to adverse events and intolerability in dementia patients.

Original languageEnglish
Pages (from-to)683-687
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume30
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Risperidone
Antipsychotic Agents
Alzheimer Disease
Clinical Trials
Area Under Curve
Behavioral Symptoms
Delusions
Therapeutic Uses
Survival Analysis
Dementia
Paliperidone Palmitate
Body Mass Index
Therapeutics
Regression Analysis
Equipment and Supplies

Keywords

  • 9-OH risperidone
  • Alzheimer's disease
  • treatment discontinuation

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial. / Wessels, Alette M.; Pollock, Bruce G.; Anyama, Norbert G.; Schneider, Lon S.; Lieberman, Jeffrey A.; Marder, Stephen R.; Bies, Robert.

In: Journal of Clinical Psychopharmacology, Vol. 30, No. 6, 12.2010, p. 683-687.

Research output: Contribution to journalArticle

Wessels, Alette M. ; Pollock, Bruce G. ; Anyama, Norbert G. ; Schneider, Lon S. ; Lieberman, Jeffrey A. ; Marder, Stephen R. ; Bies, Robert. / Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial. In: Journal of Clinical Psychopharmacology. 2010 ; Vol. 30, No. 6. pp. 683-687.
@article{edbb0712381f48e4a0bed34d375ae3ae,
title = "Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial",
abstract = "Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial that received risperidone were included in this study. Eighteen subjects completed the study without switching medication (completers on risperidone), whereas 47 discontinued the medication. Those who discontinued were divided into 2 groups according to responsiveness to therapy. Using Cox proportional survival regression analysis, we estimated time to discontinuation and factors associated with treatment discontinuation including age, dose, body mass index, neuropsychiatric inventory baseline score, and average exposure (area under the curve [AUC]) to risperidone and 9-hydroxy risperidone. Twenty-four and 17 subjects discontinued therapy because of inadequate therapeutic effect and side effects, respectively (6 subjects were excluded because of missing information about reason for switching or discontinuation). Discontinuation hazards for those with a higher than median AUC of the metabolite were 2.54 (P = 0.029; inadequate and side effect group combined) and 3.48 (P = 0.025; inadequate effect group) times that of those in the lower than median AUC group. None of the other covariates contributed significantly to the switching hazard. Risperidone metabolite, 9-hydroxy risperidone concentrations, correlated with the risk of switching or discontinuing the medication, suggesting that 9-hydroxy risperidone contributes to adverse events and intolerability in dementia patients.",
keywords = "9-OH risperidone, Alzheimer's disease, treatment discontinuation",
author = "Wessels, {Alette M.} and Pollock, {Bruce G.} and Anyama, {Norbert G.} and Schneider, {Lon S.} and Lieberman, {Jeffrey A.} and Marder, {Stephen R.} and Robert Bies",
year = "2010",
month = "12",
doi = "10.1097/JCP.0b013e3181fa05bb",
language = "English",
volume = "30",
pages = "683--687",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-alzheimer's disease trial

AU - Wessels, Alette M.

AU - Pollock, Bruce G.

AU - Anyama, Norbert G.

AU - Schneider, Lon S.

AU - Lieberman, Jeffrey A.

AU - Marder, Stephen R.

AU - Bies, Robert

PY - 2010/12

Y1 - 2010/12

N2 - Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial that received risperidone were included in this study. Eighteen subjects completed the study without switching medication (completers on risperidone), whereas 47 discontinued the medication. Those who discontinued were divided into 2 groups according to responsiveness to therapy. Using Cox proportional survival regression analysis, we estimated time to discontinuation and factors associated with treatment discontinuation including age, dose, body mass index, neuropsychiatric inventory baseline score, and average exposure (area under the curve [AUC]) to risperidone and 9-hydroxy risperidone. Twenty-four and 17 subjects discontinued therapy because of inadequate therapeutic effect and side effects, respectively (6 subjects were excluded because of missing information about reason for switching or discontinuation). Discontinuation hazards for those with a higher than median AUC of the metabolite were 2.54 (P = 0.029; inadequate and side effect group combined) and 3.48 (P = 0.025; inadequate effect group) times that of those in the lower than median AUC group. None of the other covariates contributed significantly to the switching hazard. Risperidone metabolite, 9-hydroxy risperidone concentrations, correlated with the risk of switching or discontinuing the medication, suggesting that 9-hydroxy risperidone contributes to adverse events and intolerability in dementia patients.

AB - Risperidone has been used to treat behavioral symptoms, such as delusions and agitation, in people with Alzheimer's disease. The relationship between magnitude and variability of risperidone and 9-hydroxy risperidone exposure and the relationship with time to discontinuation of the medication were explored. Sixty-five subjects from the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial that received risperidone were included in this study. Eighteen subjects completed the study without switching medication (completers on risperidone), whereas 47 discontinued the medication. Those who discontinued were divided into 2 groups according to responsiveness to therapy. Using Cox proportional survival regression analysis, we estimated time to discontinuation and factors associated with treatment discontinuation including age, dose, body mass index, neuropsychiatric inventory baseline score, and average exposure (area under the curve [AUC]) to risperidone and 9-hydroxy risperidone. Twenty-four and 17 subjects discontinued therapy because of inadequate therapeutic effect and side effects, respectively (6 subjects were excluded because of missing information about reason for switching or discontinuation). Discontinuation hazards for those with a higher than median AUC of the metabolite were 2.54 (P = 0.029; inadequate and side effect group combined) and 3.48 (P = 0.025; inadequate effect group) times that of those in the lower than median AUC group. None of the other covariates contributed significantly to the switching hazard. Risperidone metabolite, 9-hydroxy risperidone concentrations, correlated with the risk of switching or discontinuing the medication, suggesting that 9-hydroxy risperidone contributes to adverse events and intolerability in dementia patients.

KW - 9-OH risperidone

KW - Alzheimer's disease

KW - treatment discontinuation

UR - http://www.scopus.com/inward/record.url?scp=78649382300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649382300&partnerID=8YFLogxK

U2 - 10.1097/JCP.0b013e3181fa05bb

DO - 10.1097/JCP.0b013e3181fa05bb

M3 - Article

C2 - 21105282

AN - SCOPUS:78649382300

VL - 30

SP - 683

EP - 687

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -